Patient with #KRAS p.G12c mutant, advanced #NSCLC receiving #Sotorasib treatment within the Italian EAP/CUP. An 𝗔𝗧𝗟𝗔𝗦 study now being presented by Maria Lucia Reale at #AIOM23. AIOM Umberto Malapelle Giancarlo Troncone 4oncommunity

“Meet2Talk- percorsi condivisi sul tumore al polmone in fase precoce” è un incontro dedicato ai pazienti e ai loro parenti che affrontano tutti i giorni questa malattia, per chiarire i loro dubbi e condividere esperienze. Per info: bit.ly/4733ojM Vi aspettiamo !

Ricordiamo a tutti l’imminente corso residenziale “Tumori Polmonari Tra Presente e Futuro” in programma il 2 dicembre 2023. Faremo il punto su stato dell’arte e prospettive future con esperti da tutta Italia. Vi aspettiamo!

Dr. Rafael Rosell has just received the International Society of Liquid Biopsy Lifetime Achievement Award for his outstanding and inspiring career! 👏🏻 👏🏻 🥇Christian Rolfo Umberto Malapelle @MCristofanill David Gandara #ISLB23

Manca poco a "Meet2Talk: Percorsi condivisi sul tumore al polmone in fase precoce" per pazienti e caregiver. L'incontro si svolgerà a Genova il 7 dicembre alle 10:30, presso Palazzo Ducale – Sala Liguria. #Meet2Talk #TumoreAlPolmone #Genova Ospedale San Martino Genova Università di Genova AIOM

How to integrate personalized approaches into SCLC management? Genomic/transcriptomic subtyping, differential molecular expression, spontaneous lineage transformation, and liquid biopsy. mdpi.com/2611864 #mdpiijms Filippo Dall'Olio Carlo Genova

Out now on Lung Cancer Journal the real-world data on Sotorasib activity in KRAS G12C-mut NSCLC from the Italian EAP. Another important study coming from the Biomarkers Atlas platform. Congrats Francesco and Maria Lucia Reale for leading this project. lungcancerjournal.info/article/S0169-…

Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment ⁦JCO Precision Oncology⁩ ⁦International Society of Liquid Biopsy⁩ ⁦Alessandro Russo⁩ ⁦Marzia Del Re, PharmD, PhD⁩ ⁦Geoff Oxnard MD⁩ ⁦The Tisch Cancer Institute⁩ ⁦ASCO⁩ ascopubs.org/doi/10.1200/PO…

Our RW study of first-line pembrolizumab plus platinum-pemetrexed in Italian patients with advanced non-squamous lung cancer is out on Eur J Cancer! ➡️ 1068 pts ➡️ mOS 16.1m, mPFS 9.9m, ORR 43.4% ➡️ Favourable outcomes in PD-L1 < 1% 👉 ejcancer.com/article/S0959-… Great teamwork!

Corso Residenziale Corso avanzato sui tumori pleuropolmonari Resp. Scientifico: Francesco Grossi Genova | 24-25 maggio 2024 fad.accmed.org/course/info.ph… Disponibili quote gratuite fino a esaurimento posti #lungcancer #tumoripleuropolmonari #oncologia Carlo Genova Nicola Normanno

#ARTICUNO study finally published! ESMO Open 📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib 🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms 🔎 #E709 mut->lack of benefit

Corso Residenziale 🔸Young to Young 2024. L'oncologia di domani Responsabili Scientifici: Carlo Genova, Alessia Levaggi, Alessandro Pastorino, Francesco Spagnolo Genova | 11-12 ottobre 2024 Crediti ECM: 9 per info e iscrizioni: fad.accmed.org/course/info.ph… 📩 [email protected]

Digital Event 🔸Intelligenza Artificiale e oncologia. Focus sul carcinoma del polmone Responsabili Scientifici: Carlo Genova, arsela prelaj Online | 13 novembre 2024 (15:00 > 16:30) Crediti ECM: 1.5 per info e iscrizioni: fad.accmed.org/course/info.ph… 📩 [email protected]

Honored to present our center's data on the issue of diagnostic delay in patients affected by lung cancer. Grateful to Professor Carlo Genova for the guidance in evaluating perspectives different from the usual. ESMO - Eur. Oncology OncoAlert Ospedale San Martino Genova #ESMO24

Si sta avvicinando la nuova edizione del corso "TUMORI POLMONARI TRA PRESENTE E FUTURO" a Genova. Sarà un'occasione di aggiornamento su stato dell'arte e prospettive nelle neoplasie polmonari. Per iscriversi: fad.accmed.org/course/info.ph… Vi aspettiamo! Accademia Medicina WALCE APS

Eventually, this titanic networking effort is out Journal for ImmunoTherapy of Cancer 🎯 If properly managed, RWE can be highly informative— in this GLOBAL 5-year cohort study of 1L pembro in #NSCLC we used ESMO - Eur. Oncology-GROW👇Recommended! UCBM Surgery and Cancer jitc.bmj.com/content/13/2/e…

Kinase Domain Duplications (KDD) are complex rearrangements and rare resistance mechanisms to kinase inhibitors. We report the first case of acquired BRAF-KDD in a patient with #BRAF V600E+ #NSCLC treated with dabrafenib-trametinib. JCO Precision Oncology ascopubs.org/doi/10.1200/PO…

Approval of TROP 2 ADC in EGFR+ NSCLC previously treated with EGFR TKI(s).

Correlation between treatments&outcomes of pts with EGFR-mutated NSCLC that transitioned into SCLC: an international retrospective study in ESMO Open. Poor outcomes despite treatment, primary EGFR mutation maintained upon transformation. esmoopen.com/article/S2059-…

Bravo Francesco !!